UP421

July 1, 2026: Sana Biotechnology, Inc. (NASDAQ: SANA) announced it will present clinical data at a symposium during the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 (Sept. 28–Oct. 2, 2026; Milan, Italy) from an investigator-sponsored, first-in-human study transplanting UP421—an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune platform (HIP) technology—into a patient with type 1 diabetes without any immunosuppression. The presentation (“Hypoimmune islets: engineering immune evasion for durable transplantation without immunosuppression”) is scheduled for Friday, Oct. 2, 2026, 9:10–9:30 a.m. CEST, within the symposium “Stem cell-derived islets in clinical trials: towards a cure for type 1 diabetes.”